Global Information
회사소개 | 문의 | 비교리스트

칸나비디올(CBD) 통증 : 역학 인사이트(-2030년)

Cannabidiol (CBD) Pain - Epidemiology Insight - 2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 966760
페이지 정보 영문 100 Pages
가격
US $ 3,750 ₩ 4,509,000 PDF (Single User License)
US $ 7,500 ₩ 9,018,000 PDF (Site License)
US $ 11,250 ₩ 13,528,000 PDF (Global License)


칸나비디올(CBD) 통증 : 역학 인사이트(-2030년) Cannabidiol (CBD) Pain - Epidemiology Insight - 2030
발행일 : On Demand Report 페이지 정보 : 영문 100 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스, 영국) 및 일본 7개 주요 시장의 칸나비디올(CBD) 통증 시장에 대해 상세하게 설명했으며, 질환 배경과 개요, 미충족 수요, 각국의 역학, 치료법 등에 관한 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 주요 요약

제3장 칸나비디올(CBD) 통증 : 질환 배경과 개요

  • 서론
  • 징조와 증상
  • 병태생리학
  • 위험인자
  • 진단

제4장 환자 여정

제5장 역학과 환자 인구

  • 역학 주요 조사 결과
  • 가정과 이론적 근거 : 주요 7개국
  • 역학 시나리오 : 주요 7개국
    • 주요 7개국의 칸나비디올(CBD) 통증 역학 시나리오
  • 미국의 역학
    • 미국의 칸나비디올(CBD) 통증 역학 시나리오
  • 유럽 5개국의 역학 : 국가별
    • 독일의 역학
    • 프랑스의 역학
    • 이탈리아의 역학
    • 스페인의 역학
    • 영국의 역학
  • 일본의 역학
    • 일본의 칸나비디올(CBD) 통증 역학 시나리오

제6장 치료 알고리즘, 현재 치료 및 의료 행위

  • 칸나비디올(CBD) 통증 치료와 관리
  • 칸나비디올(CBD) 통증 치료 알고리즘

제7장 KOL의 견해

제8장 미충족 수요

제9장 부록

  • 참고문헌
  • 보고서 조사 방법

제10장 DelveInsight 서비스 내용

제11장 면책사항

제12장 DelveInsight 소개

KSM 20.11.04

List of Tables

  • Table 1: Cannabidiol (CBD) Pain Epidemiology in 7MM (2017-2030)
  • Table 2: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Cannabidiol (CBD) Pain Epidemiology in the United States (2017-2030)
  • Table 4: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Cannabidiol (CBD) Pain Epidemiology in Germany (2017-2030)
  • Table 6: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Cannabidiol (CBD) Pain Epidemiology in France (2017-2030)
  • Table 8: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Cannabidiol (CBD) Pain Epidemiology in Italy (2017-2030)
  • Table 10: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Cannabidiol (CBD) Pain Epidemiology in Spain (2017-2030)
  • Table 12: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Cannabidiol (CBD) Pain Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Cannabidiol (CBD) Pain Epidemiology in Japan (2017-2030)
  • Table 16: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Cannabidiol (CBD) Pain Epidemiology in 7MM (2017-2030)
  • Figure 2: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Cannabidiol (CBD) Pain Epidemiology in the United States (2017-2030)
  • Figure 4: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Cannabidiol (CBD) Pain Epidemiology in Germany (2017-2030)
  • Figure 6: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Cannabidiol (CBD) Pain Epidemiology in France (2017-2030)
  • Figure 8: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Cannabidiol (CBD) Pain Epidemiology in Italy (2017-2030)
  • Figure 10: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Cannabidiol (CBD) Pain Epidemiology in Spain (2017-2030)
  • Figure 12: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Cannabidiol (CBD) Pain Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Cannabidiol (CBD) Pain Epidemiology in Japan (2017-2030)
  • Figure 16: Cannabidiol (CBD) Pain Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

DelveInsight's 'Cannabidiol (CBD) Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Cannabidiol (CBD) Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Cannabidiol (CBD) Pain Understanding

The DelveInsight Cannabidiol (CBD) Pain epidemiology report gives a thorough understanding of the Cannabidiol (CBD) Pain by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cannabidiol (CBD) Pain in the US, Europe, and Japan. The report covers the detailed information of the Cannabidiol (CBD) Pain epidemiology scenario in seven major countries (US, EU5, and Japan).

Cannabidiol (CBD) Pain Epidemiology Perspective by DelveInsight

The Cannabidiol (CBD) Pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cannabidiol (CBD) Pain epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Cannabidiol (CBD) Pain epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Cannabidiol (CBD) Pain Detailed Epidemiology Segmentation

The Cannabidiol (CBD) Pain epidemiology covered in the report provides historical as well as forecasted Cannabidiol (CBD) Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Cannabidiol (CBD) Pain report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Cannabidiol (CBD) Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Cannabidiol (CBD) Pain Epidemiology Report and Model provide an overview of the risk factors and global trends of Cannabidiol (CBD) Pain in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Cannabidiol (CBD) Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Cannabidiol (CBD) Pain
  • The report provides the segmentation of the Cannabidiol (CBD) Pain epidemiology

Report Highlights:

  • 11-Year Forecast of Cannabidiol (CBD) Pain epidemiology
  • 7MM Coverage
  • Total Cases of Cannabidiol (CBD) Pain
  • Total Cases of Cannabidiol (CBD) Pain according to segmentation
  • Diagnosed cases of Cannabidiol (CBD) Pain

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cannabidiol (CBD) Pain ?
  • What are the key findings pertaining to the Cannabidiol (CBD) Pain epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Cannabidiol (CBD) Pain across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Cannabidiol (CBD) Pain ?
  • What are the currently available treatments of Cannabidiol (CBD) Pain ?

Reasons to buy:

  • The Cannabidiol (CBD) Pain Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Cannabidiol (CBD) Pain market
  • Quantify patient populations in the global Cannabidiol (CBD) Pain market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cannabidiol (CBD) Pain therapeutics in each of the markets covered
  • Understand the magnitude of Cannabidiol (CBD) Pain population by its epidemiology
  • The Cannabidiol (CBD) Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Cannabidiol (CBD) Pain

3. Cannabidiol (CBD) Pain : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Cannabidiol (CBD) Pain Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Cannabidiol (CBD) Pain Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Cannabidiol (CBD) Pain Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Cannabidiol (CBD) Pain Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Cannabidiol (CBD) Pain Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Cannabidiol (CBD) Pain Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Cannabidiol (CBD) Pain Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Cannabidiol (CBD) Pain Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Cannabidiol (CBD) Pain Treatment and Management
  • 6.2. Cannabidiol (CBD) Pain Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

Back to Top
전화 문의
F A Q